Immunoglobulin superfamily member 8 is a protein that in humans is encoded by the IGSF8gene.[5][6][7] IGSF8 has also been designated as CD316 (cluster of differentiation 316). IGSF8 is an innate immune checkpoint that inhibits the cytotoxic activity of natural killer (NK) cells.[8] IGSF8 acts by binding to the Killer Ig-like Receptor KIR3DL2 (or, in mice, the analogous Klra9 receptor).[8] IGSF8 is frequently overexpressed relative to normal tissues in many cancers, included melanoma, urothelial carcinoma, and breast cancer,[8] and has been proposed as a potential therapeutic target in gliomas.[9] In normal tissues, IGSF8 is highly expressed in the brain, where it may contribute to the immune privilege of the central nervous system.[8]
IGSF8 as a Cancer Biomarker
In gliomas, IGSF8 is strongly correlated with tumor grade and is a potential prognostic marker.[9] IGSF8 is enriched on ovarian cancer-derived extracellular vesicles and is a potential biomarker for the early detection of high grade serous ovarian cancer.[10]
Zhang XA, Lane WS, Charrin S, et al. (2003). "EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells". Cancer Res. 63 (10): 2665–74. PMID12750295.
Bonkobara M, Das A, Takao J, et al. (2003). "Identification of novel genes for secreted and membrane-anchored proteins in human keratinocytes". Br. J. Dermatol. 148 (4): 654–64. doi:10.1046/j.1365-2133.2003.05244.x. PMID12752121. S2CID21635573.
